LAV Biosciences Fund V, L.P., identified as a 10% owner of ADARx Pharmaceuticals, Inc. (ADRX), reported a derivative conversion involving 8,908,775 shares on September 28, 2026, according to an SEC filing summary. The supplied material lists six transactions in the filing and indicates no Rule 10b5-1 plan.

The source item carries a September 30, 2026, publication timestamp. That establishes the publication date provided for this report; the supplied facts do not separately confirm the filing's submission date.

What the SEC summary reports

The reported transaction is a conversion involving a derivative security. The summary supplies a share amount and transaction date, but does not identify the underlying instrument, conversion terms, transaction price or any proceeds.

It also does not break down the filing's six transactions. Accordingly, the 8,908,775-share figure should not be treated as six separate conversions of that size, or as a complete accounting of every transaction in the filing.

The source headline names LAV Fund VI, L.P., while the transaction summary identifies LAV Biosciences Fund V, L.P. as the 10% owner. Those are different fund names. The supplied material does not explain their relationship or establish why both appear in the source information.

What the disclosure cannot establish

A derivative conversion alone does not establish an open-market purchase or sale. The summary also cannot establish whether the reporting owner's economic exposure increased or decreased, whether cash changed hands, or how many shares remained afterward.

The indication that no Rule 10b5-1 plan was involved does not explain the transaction's purpose or the owner's investment outlook.

Analysis: The disclosure is relevant to tracking a reported large shareholder's securities activity. Its limited detail makes it insufficient evidence, by itself, of a bullish or bearish investment decision.

What to watch

The full filing would be the next document to examine for the submission date, the relationship between the named funds, conversion terms, the six transaction entries and any reported ownership balances.